http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
HBeAg 양성 만성활동성간염에 있어서 α2b - Interferon ( IFN ) 의 치료 반응에 대한 전조요인에 관한 연구 - IFN 치료 전후 검사소견을 중심으로 -
김세종(Sei Jong Kim),김형원(Hyung Won Kim),양동욱(Dong Wook Ryang) 대한소화기학회 1993 대한소화기학회지 Vol.25 No.6
N/A To have the knowledge for the factors predicting response to a2b-interferon (IFN) therapy, 3 million units of a2b-Interferon (Intron-AR: Shering Co., U.S.A.) was injected subcutaneously 3 times a week for 12 weeks in 23 patients with HBeAg postitive CAH (male: 17, female: 6). The subjects were divided into two groups according to the seroconversion of HBeAg after IFN therapy. One is responder group which HBeAg is negative consecutively more than 24 weeks, the other is nonresponder group which HBeAg is negative less than 24 weeks. The statistical analysis of the pretreatment data of two groups was made. In routine examination except platelets in peripheral blood, there were no significant changes before and after a2b-Interferon therapy. But platelets was begun to decrease significantly (p<0.05) from the 4th to the 8th week with IFN therapy and th pretreatment platelets were lowered very significantly (p<0.005) to the low normal level around 130 thousand per cubic milimeter in the responder. So subcutaneous injection of 3 million units three times a week for 12 week may be safe in HBeAg positive CAH. In liver function tests, serum AST and ALT were markedly increased in pretreatment status as 231. 7+- 134.9 I U and 403.6+- 186.7 IU respectively. But these began to decrease from the 4th week after IFN therapy. It fall down significantly from the 8th to the 116th week after the therapv (p<0.01). Serum albumn levels were within normal range before and after the therapy. But it increased more significantly (p <0.005) within normal range frorn 4th to the 64th week with the therapy in the responder. There were significant differences in pretreatment level of serum AST and albumin between two groups (p<0.05). HBeAg negativity was more than 26% from the 48th week after therapy. HBV DNA levels were 418.3+-835.3 pg/75 ul in pretreatment status. It began to decrease significantly frorn the 4th week to..... (continue..)
한국 성인에서 C 형 간염바이러스 항체 양성율에 관한 고찰
한상우(Sang Woo Han),박용욱(Yong Uk Park),김신묵(Sin Mook Kim),신동현(Dong Hyun Shin),서순팔(Soon Pal Suh),양동욱(Dong Wook Ryang),김세종(Sei Jong Kim) 대한내과학회 1994 대한내과학회지 Vol.47 No.6
N/A Objectives : HCV, which is well known major cause of posttransfusion hepatitis, is single strand RNA virus. ELISA to anti-HCV was developed in 1989 and has been used widely after that. There were a lot of studies about positivity of anti-HCV which supposed the prevalence of HCV in Korea. Subjects of previous studies were restricted in healthy blood donor or patients with liver diseases. It was hard to evaluate the prevalence of HCV in whole population. We studied the positivity of anti-HCV in Korean adults, Methods : We studied the positivity of anti-HCV (by EIA method) and the relationship with HBsAg, ALT or age in 1,D13 Korean adults. Results : 1) The positivity of anti-HCV was 0.9% (9 of 1013). 2) There was no difference in the positivity of anti-HCV by the sex: 0.9% in male (6/695) and female (3/318). But it increased with age: 0.4% in 3rd decade, 0.6% in 4th decade, 0.8% in 5th decade, and 2.5% in 6th decade. 3) Of 9 anti-HCV positive cases, serum ALT level was up to 40 U/L in 8 cases, but serum ALT was 65 U/L in one case. 4) The positivity of HBsAg was 59 (51 of 1,013), but HBsAg was negative in 9 anti-HCV positive cases. Conclusion : The positivity of anti-HCV in Korean adults was regarded to be lower than l% and it in- creased with age.
호중구감소증과 연관된 중증 감염 환자에게 과립구집락자극인자와 덱사메사손으로 가동화된 정상 공여자로부터 과립구 수혈치료
이병환 ( Byoung Hwan Lee ),이제중 ( Je Jung Lee ),김여경 ( Yeo Kyeoung Kim ),조상희 ( Sang Hee Cho ),신동현 ( Dong Hyeon Shin ),조덕 ( Duck Cho ),양동욱 ( Dong Wook Ryang ),박무림 ( Moo Rim Park ),정익주 ( Ik Joo Chung ),김형준 ( 대한내과학회 2003 대한내과학회지 Vol.64 No.4
목적 : 과립구 수혈치료는 적절한 항생제의 사용에도 불구하고 반응을 보이지 않는 호중구감소증과 연관된 중증 감염에 이용되어 왔다. 정상 공여자에게 백혈구를 가동화시키기 위하여 백혈구 조혈촉진인자나 스테로이드가 이용되어 왔으나, 최근에는 이를 병합하여 사용하는 추세이다. 본 연구는 과립구집락자극인자와 dexamethasone 병합 요법을 이용하여 공여자로부터 과립구를 채집한 후, 호중구감소증과 연관된 중증 감염 환자를 대상으로 과립구 수혈치료를 시행하여서 Background : Granulocyte transfusions have been used to treat severe, progressive infections in neutropenic patients who fail to respond to antimicrobial agents. Although corticosteroid or granulocyte colony-stimulating factor (G-CSF) were previously used